JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 32 No. 4 616-622
© 1991 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coleman, R. E.
Right arrow Articles by Schold, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coleman, R. E.
Right arrow Articles by Schold, S. C.

Clinical Application of PET for the Evaluation of Brain Tumors

R. Edward Coleman, John M. Hoffman, Michael W. Hanson, H. Dirk Sostman and S. Clifford Schold

Departments of Radiology and Internal Medicine (Neurology), Duke University Medical Center, Durham, North Carolina

Correspondence: For reprints contact: R. Edward Coleman, MD, Box 3949, Duke University Medical Center, Durham, NC 27710.

ABSTRACT

The combination of FDG and PET has demonstrated clinical utility in the evaluation of patients with brain tumors. At the time of diagnosis, FDG PET provides information concerning the degree of malignancy and patient prognosis. After therapy, FDG PET is able to assess persistence of tumor, determine degree of malignancy, monitor progression, differentiate recurrence from necrosis, and assess prognosis. Other studies using PET provide information that may be clinically useful. Determination of tumor blood flow and permeability of the blood-brain barrier may help in the selection of appropriate therapy. Amino acid imaging using 11C-methionine is being evaluated in patients with brain tumors and provides different information than FDG imaging.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D S Rosenberg, G Demarquay, A Jouvet, D Le Bars, N Streichenberger, M Sindou, N Kopp, F Mauguiere, and P Ryvlin
[11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms
J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1686 - 1692.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Takahashi, Y. Imahori, and K. Mineura
Prognostic and Therapeutic Indicator of Fluoroboronophenylalanine Positron Emission Tomography in Patients with Gliomas
Clin. Cancer Res., December 1, 2003; 9(16): 5888 - 5895.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. M. Rohren, J. M. Provenzale, D. P. Barboriak, and R. E. Coleman
Screening for Cerebral Metastases with FDG PET in Patients Undergoing Whole-Body Staging of Non-Central Nervous System Malignancy
Radiology, January 1, 2003; 226(1): 181 - 187.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Spence, M. Muzi, M. M. Graham, F. O'Sullivan, J. M. Link, T. K. Lewellen, B. Lewellen, S. D. Freeman, D. A. Mankoff, J. F. Eary, et al.
2-[18F]Fluoro-2-deoxyglucose and Glucose Uptake in Malignant Gliomas before and after Radiotherapy: Correlation with Outcome
Clin. Cancer Res., April 1, 2002; 8(4): 971 - 979.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. D. Langleben and G. M. Segall
PET in Differentiation of Recurrent Brain Tumor from Radiation Injury
J. Nucl. Med., November 1, 2000; 41(11): 1861 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
D. P. Frush, L. F. Donnelly, and H. G. Chotas
Contemporary Pediatric Thoracic Imaging
Am. J. Roentgenol., September 1, 2000; 175(3): 841 - 851.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. J. Aronen, F. S. Pardo, D. N. Kennedy, J. W. Belliveau, S. D. Packard, D. W. Hsu, F. H. Hochberg, A. J. Fischman, and B. R. Rosen
High Microvascular Blood Volume Is Associated with High Glucose Uptake and Tumor Angiogenesis in Human Gliomas
Clin. Cancer Res., June 1, 2000; 6(6): 2189 - 2200.
[Abstract] [Full Text]

Home page
 Am. J. Neuroradiol.Home page
K. Fukuchi, K. Hayashida, H. Moriwaki, K. Fukushima, N. Kume, T. Katafuchi, M. Sago, M. Takamiya, and Y. Ishida
Brain Fluorine-18 Fluorodeoxyglucose Imaging with Dual-Head Coincidence Gamma Camera:Comparison with Dedicated Ring-Detector PositronEmission Tomography
AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 99 - 104.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
A. M. Kaplan, M. A. Lawson, J. Spataro, D. J. Bandy, C. T. Bonstelle, S. D. Moss, K. H. Manwaring, and E. M. Reiman
Positron Emission Tomography Using [18F] Fluorodeoxyglucose and [ 11C] L-Methionine to Metabolically Characterize Dysembryoplastic Neuroepithelial Tumors
J Child Neurol, October 1, 1999; 14(10): 673 - 677.
[Abstract] [PDF]

Home page
 RadiologyHome page
E. M. Marom, H. P. McAdams, J. J. Erasmus, P. C. Goodman, D. K. Culhane, R. E. Coleman, J. E. Herndon, and E. F. Patz Jr
Staging Non-Small Cell Lung Cancer with Whole-Body PET
Radiology, September 1, 1999; 212(3): 803 - 809.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
R O Robinson, C D Ferrie, M Capra, and M N Maisey
Positron emission tomography and the central nervous system
Arch. Dis. Child., September 1, 1999; 81(3): 263 - 270.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1991 by the Society of Nuclear Medicine.